Optiscan Imaging in Mulgrave, Victoria | Medical and health

Optiscan Imaging

Locality: Mulgrave, Victoria

Phone: +61 3 9538 3333

Address: 16 Miles Street 3170 Mulgrave, VIC, Australia

Website: http://www.optiscan.com

Likes: 32

Add/Update information

Reviews

Tags

• Medical and health

25.01.2022 Optiscan Investor presentation presented by Darren Lurie at the Emergence Conference in Sydney 28th February 2020 Full Video: https://youtu.be/o0koUscEzFM

24.01.2022 Optiscan Chairman Darren Lurie presents to Chinese distributors and health care professionals in todays webinar: Zhejiang Overseas Online Matchmaking Conference Life Sciences & Healthtech; Australia Session Sign up here to join: https://lnkd.in/gNUZpKq

24.01.2022 Zeiss will be at EANS between September 24-29, 2019 to showcase the all-new concept of ZEISS Tumor Workflow and gain the first-hand experience of working with CONVIVO https://www.zeiss.com//int/media-news/events/eans-2019.html

24.01.2022 CONVIVO clinical trial at the Technical University of Munich Digitally connecting the CONVIVO in the operating theatre with the pathologist to help the surgeon evaluate the tumour margin in real time. https://www.ncbi.nlm.nih.gov/pubmed/30942755

23.01.2022 Excited to share that Optiscan has been awarded a Medical Research Future Fund (MRFF) grant of almost $1 million, which will help fund a trial at the Melbourne Dental School to improve screening, diagnosis and treatment of oral cancer. Oral cancer is one of the most common cancers globally. Our technology is making oral cancer screening less invasive and more efficient, enabling early diagnosis and surgical treatment. A big shout out to Professor Michael McCullough, Dr Tami Y...ap, and Jerome Wielens at University Of Melbourne Dental School. We look forward to working with you on this important project. The funding is provided via the BioMedTech Horizons (BMTH) program, an initiative of the MFRR, operated by the MTPConnect. It is designed to foster innovative collaborative health technology development, and stimulate collaboration across disciplines and between the research, industry, and technology sectors to maximise entrepreneurship and idea potential. Minister Greg Hunts announcement: https://www.health.gov.au//188-million-to-supercharge-digi Optiscans media release: https://www.optiscan.com//government-grant-to-support-mel/

22.01.2022 Corporate Update Additional Cash Receipts Expected Full Details - https://bit.ly/2U8gGc9

22.01.2022 We are delighted to announce that Optiscan CEO and chair Darren Lurie is to present at the Emergence 2020 Conference in Sydney on 28 February 2020 Showcasing Optiscan Technology.

22.01.2022 Optiscan Investor presentation presented by Darren Lurie at the AusBiotech Conference Melb 30th Oct - 1st Nov 2019. See Full Presentation: https://bit.ly/2Ww5Rjk

22.01.2022 A new study validating OptiScan’s endomicroscopic technology has this week been published in Nature Biomedical Engineering, one of the world’s leading medical research journals. The study, led by Memorial Sloan Kettering Cancer Centre, found that OptiScan’s ViewnVivo has the potential to be used for intraoperative, PARPi-FL-based in vivo imaging without tissue excision. OptiScan’s technology enables real-time, 3D, in vivo imaging of human tissue at the cellular level. It pr...ovides instant virtual biopsies for cancer screening, diagnoses, and treatment. For more on the study, visit: https://www.nature.com/articles/s41551-020-0526-9

21.01.2022 OptiScan’s partnership with the University of Melbourne’s Melbourne Dental School to undertake a trial to improve screening and early diagnosis of oral cancer has received almost $1million dollars of Federal Government funding and is scheduled to start in September. You can read more about this exciting project here: https://pursuit.unimelb.edu.au//towards-the-early-detectio

21.01.2022 2 x China Tender Success for FIVE2 (ViewnVivo). Formal orders are expected to be received next month with revenues in excess of A$350k to be received from the 2 sales. Read the full announcement here: https://www.asx.com.au/asxp/20200728/pdf/44kwsrnh7dh6sj.pdf

21.01.2022 Optiscan is collaborating with CSIRO Team Leader Prof. Sally McArthur and Post Doctoral fellow Dr. Geva Hilzenrat to establish protocols for real-time imaging of in-vitro 3D tissue cultures. Utilizing Optiscans FIVE2 (ViewnVivo) confocal endomicroscope, CSIRO and Optiscan have developed an application note for imaging tissue culture samples inside a biosafety cabinet or incubator. View The Application Note Here: https://bit.ly/2PTedjU

20.01.2022 World leading hospitals Peter Mac & US Sloan Kettering collaboration to trial Optiscans leading Cancer Imaging System. Key Highlights: The Melbourne Dental School (University of Melbourne) is seeking ethics approval for the use of Optiscans clinical imaging system as part of a human clinical trial to diagnose cancerous change in oral mucosa at the earliest possible stage (Oral Cancer Trial).... Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Memorial Sloan Kettering Cancer Centre and Australian Centre for Oral Oncology Research & Education (Collaborators) are collaborators in the Oral Cancer Trial. 2nd Oral Cancer Clinical Trial by World-Leading Hospitals targeting Oral Cancer Screening using the Optiscan system. Full Details https://www.asx.com.au/asx/share-price-research/company/OIL

20.01.2022 Dr Philip Currie and Lindsay Bussau, PhD presenting on Confocal Endomicroscopy and Breast Cancer at The 17th World Federation for Ultrasound in Medicine and Biology Congress, Melb 6-9th Sept 2019.

20.01.2022 Optiscan delivery on its way to Carl Zeiss Meditec!

19.01.2022 Watch the latest Carl Zeiss Meditech Video: CONVIVO is a key part of the Carl Zeiss Meditech standard of care for brain tumour surgery CONVIVO developed by the Optiscan Carl Zeiss Meditech collaboration project. Click the link to watch the full video. https://www.zeiss.com/medit/int/c/tumor-workflow-video.html

19.01.2022 Check out the latest from Memorial Sloan Kettering Cancer Center researchers on PARPi-FL applied Oral Cancer tumour resection using Optiscans handheld confocal technology published in Natures - Scientific Reports. Important research, as Optiscan pursues FDA approval for its oral cancer screening and surgical margin detection device, InVivage. Publication link: https://www.nature.com/articles/s41598-020-67958-8... #imageguidedsurgery #liveconfocalimaging #oralcancer #oralhealth #Opticalbiopsy #endomicroscopy

19.01.2022 Optiscan's presentation at the FNN Online Investor Event. Executive Chairman Darren Lurie presents on the company's handheld confocal, endomicroscopes that provide instantaneous, virtual, biopsy-like images for human cancer screening.

19.01.2022 A new study validating OptiScans endomicroscopic technology has this week been published in Nature Biomedical Engineering, one of the worlds leading medical research journals. The study, led by Memorial Sloan Kettering Cancer Centre, found that OptiScans ViewnVivo has the potential to be used for intraoperative, PARPi-FL-based in vivo imaging without tissue excision. OptiScans technology enables real-time, 3D, in vivo imaging of human tissue at the cellular level. It pr...ovides instant virtual biopsies for cancer screening, diagnoses, and treatment. For more on the study, visit: https://www.nature.com/articles/s41551-020-0526-9

18.01.2022 Optiscan presenter and sponsor at the BioPhotonics career workshop at Swinburne University.

16.01.2022 Our latest investor pitch at the FNN Investor Events.

16.01.2022 Optiscan is excited to announce Singapore based Clermont Group as the cornerstone investor in its $9.8m capital raising. Clermont Group’s expertise and track record make it the perfect partner for Optiscan as we accelerate our ambition to become a world-scale medical imaging and diagnostics company. https://www.optiscan.com/2020//24/optiscan-capital-raising/

16.01.2022 Optiscan's presentation at the FNN Online Investor Event. Executive Chairman Darren Lurie presents on the company's handheld confocal, endomicroscopes that provide instantaneous, virtual, biopsy-like images for human cancer screening.

15.01.2022 Great to be featured in DentistryToday's industry news. Leading clinical dental US news magazine for dentists.

14.01.2022 Next Monday - 22 June 2020 - be sure to join Carl Zeiss for the virtual launch of its new digital pathology platform. Optiscan has worked with Carl Zeiss to develop ZEISS CONVIVO, which enables the determination of the tumour margin during neurosurgery. Digital biopsies with CONVIVO require no extraction of tissue or processing, enabling surgeons to take an unlimited number of digital images which can be transferred for analysis anywhere anytime for interpretation by patholo...gists. Its a really exciting technology that is redesigning the point of care in neurosurgery. Please join us for the virtual launch. Register at: https://www.zeiss.com//in-vivo-pathology-consultation.html #digitalpathology #neurosurgery #endomicroscopy #biopsy #imaging #analysis #medicaldevices #pointofcare #zeiss #healthcare #innovation

14.01.2022 Optiscans Executive Chairman Darren Lurie presenting at the Gold Coast Investment Showcase

13.01.2022 Optiscan is proud to be sponsoring the "In Vivo Imaging" category in The Annual Light Microscopy Australia Image Competition for 2019 Full Details - https://microscopy.org.au/2019-lma-image-competition/

12.01.2022 Optiscan is working with Monash University and University of Michigan investigating alternate explanation of causes of ACL injury. Optiscan is delighted to be working with world-leading researchers Professor Mark Banaszak Holl, Professor James Ashton Miller and Dr Edward Wojtys from Monash University and the University of Michigan investigating whether material fatigue or accumulated ACL microdamage at a molecular level, rather than a single-force incident, could be to blame ...for ACL failure during normal athletic activity. Professor Banaszak Holl said that: Were very interested in endoscopes, and it turns out theres a confocal endoscope made by Optiscan Imaging, which was originally a technology developed and spun out from technology developed here at Monash University, and were working closely with them both at Monash University and at University of Michigan to try and translate this research for initial evaluation of the knee problem and for the surgical repair processThe high-resolution imaging and small diameter of their endoscope gives us some unique research and potentially surgical capabilities. Read the full story here: https://lens.monash.edu//acl-injury-epidemic-dead-legs-tel See more

12.01.2022 ..The most exciting technology that I have seen in my career come through the laboratory... -Mark C Preul-MD, Neurosurgeon, Barrow Neurosurgical Institute. Neurosurgeon Mark C Preul MD, Peter Nakaji MD and neuropathologist Jennifer Eschbacher MD from the Barrow Neurosurgical Institute in Arizona, USA - one of the worlds - leading neurosurgery hospitals; neurosurgeon Francesco Acerbi MD from the Neurological Institute Carlo Besta in Milan, Italy and Karl-Michael Schebesch M...D from the University of Regensburg Medical Centre in Germany talk about the impact of visualising tumour margin in the operating theatre with the digital biopsy tool CONVIVO, developed in collaboration with Optiscan. Professor Mark Preul MD said, I had the opportunity over many years to see technologies that come through the laboratory and I would have to say that this probably is the most exciting technology that I have seen in my career come through the laboratory. Watch Full Video: https://bit.ly/34CIwPK

10.01.2022 Dr Paula Demetrio from Memorial Sloan Kettering Cancer Centre presents at Peter MacCallum Cancer Centre & Hollywood Private Hospital. For Full News Visit - https://www.optiscan.com/investors-media/news/

09.01.2022 Next Monday - 22 June 2020 - be sure to join Carl Zeiss for the virtual launch of it's new digital pathology platform. Optiscan has worked with Carl Zeiss to develop ZEISS CONVIVO, which enables the determination of the tumour margin during neurosurgery. Digital biopsies with CONVIVO require no extraction of tissue or processing, enabling surgeons to take an unlimited number of digital images which can be transferred for analysis anywhere anytime for interpretation by patholo...gists. It's a really exciting technology that is redesigning the point of care in neurosurgery. Please join us for the virtual launch. Register at: https://www.zeiss.com//in-vivo-pathology-consultation.html #digitalpathology #neurosurgery #endomicroscopy #biopsy #imaging #analysis #medicaldevices #pointofcare #zeiss #healthcare #innovation

08.01.2022 OptiScans partnership with the University of Melbournes Melbourne Dental School to undertake a trial to improve screening and early diagnosis of oral cancer has received almost $1million dollars of Federal Government funding and is scheduled to start in September. You can read more about this exciting project here: https://pursuit.unimelb.edu.au//towards-the-early-detectio

07.01.2022 Optiscan/Pentax confocal endomicroscope used for imaging organoids. Investigating a new technique for in-vivo confirmation of stem cell implantation. Leading European and US researchers (University of Copenhagen, Harvard University and Massachusetts Institute of Technology) using Optiscan confocal laser technology in the Pentax ISC-1000 to look at the use of organoids grown from gastric mucosal stem cells to treat damaged mucosal epithelium in a new publication in Stem Cell Research & Therapy: https://doi.org/10.1186/s13287-019-1246-5 The authors conclude, It is highly feasible to use fluorescent dye-based labelling in combination with CLE to trace intestinal organoids following transplantation to confirm implantation at the intestinal target site

06.01.2022 A first look at InVivage: Optiscans new oral cancer imaging device.

06.01.2022 Optiscan March China Trip - 8 meetings in 4 cities in 5 days.

05.01.2022 Corporate Update Additional Cash Receipts Expected Full Details - https://bit.ly/2U8gGc9

03.01.2022 Optiscans presentation at the FNN Online Investor Event. Executive Chairman Darren Lurie presents on the companys handheld confocal, endomicroscopes that provide instantaneous, virtual, biopsy-like images for human cancer screening.

02.01.2022 Chairman Darren Lurie's interview with Rachael Jones from the Finance News Network (FNN).

02.01.2022 Optiscan System Approved for Prestigious Cancer Centre Trial Highlights Optiscan cutting-edge real time virtual biopsy technology approved for use in Memorial Sloan Kettering Cancer Centre oral cancer human clinical trial... Optiscan re-sterilisable sheath receives independent third-party validation Nearing completion of Stage 2 of Breast Cancer Clinical Trial at Western Australias largest private hospital, Hollywood Private Hospital On-going clinical and pre-clinical marketing initiatives and activities Full Announcement - https://www.asx.com.au/asx/share-price-research/company/OIL

02.01.2022 CEO Darren Lurie updates Proactive on the development of its new clinical system for oral cancer screening and surgery, on going clinical trials and new China distributor. Watch Full Interview - https://bit.ly/36iivqX

02.01.2022 Optiscan requests meeting with the US Food and Drug Administration (FDA) to discuss a 510(k) submission to enable the legal sale in the United States of the Optiscan system in oral cancer screening and /or surgery. See Full Announcement - https://bit.ly/32aq5Av

01.01.2022 Optiscan visit to US Food and Drug Administration in Washington DC for InVivage medical device in Oral Cancer On our late January visit to the United States, Optiscan was delighted to meet with the US Food and Drug Administration in Washington DC in relation to a 510(k) submission for the sale of the InVivage system in human Oral Cancer in the United States. It was also a great opportunity to visit Optiscans partners in the Oral Cancer trial being conducted at Memorial Sloan Kettering Cancer Centre in New York and in the Anterior Cruciate Ligament (ACL) research at the University of Michigan.